Vanda Pharmaceuticals Inc Earnings

The next earnings date for Vanda Pharmaceuticals Inc has not yet been scheduled.

Analyst Estimates of Vanda Pharmaceuticals Inc Earnings

No Results.
Report DateEstimated Earnings Per Share
No Results.

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Vanda Pharmaceuticals Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
11/05/2025Before Market$-0.3815.56%
07/29/2025Before Market------
05/06/2025Before Market$-0.50-1,100.00%
02/05/2025Before Market$-0.08---
11/06/2024After Market$-0.0943.75%
07/31/2024After Market$-0.0861.90%
05/08/2024After Market$-0.07-243.60%
02/07/2024After Market$-0.0455.56%
11/08/2023After Market$0.00106.00%
07/27/2023After Market$0.03123.08%
05/03/2023After Market$0.06---
02/08/2023After Market$0.1250.00%
11/02/2022After Market$0.06-33.33%
08/03/2022After Market$0.05-54.55%
05/05/2022After Market$-0.11-1,000.00%
02/23/2022After Market$0.1233.33%
11/03/2021After Market$0.14-22.22%
07/28/2021After Market$0.1721.43%
05/05/2021After Market$0.150.00%
02/10/2021After Market$0.157.14%
10/28/2020After Market$0.1110.00%
08/05/2020After Market$0.16300.00%
05/06/2020After Market$0.01-87.50%
02/25/2020After Market$0.08-27.27%
11/06/2019After Market$0.22214.29%
07/31/2019After Market$0.21425.00%
05/01/2019After Market$-0.01-116.67%
02/13/2019After Market$0.191,800.00%
11/07/2018After Market$0.13533.33%
08/01/2018After Market$0.09150.00%
05/02/2018After Market$0.06135.29%
02/14/2018After Market$-0.0466.67%
11/07/2017After Market$-0.109.09%
08/02/2017After Market$-0.0389.29%
05/02/2017After Market$-0.1710.53%
02/15/2017After Market$-0.0188.89%
11/02/2016After Market$-0.0187.50%
07/27/2016After Market$-0.1150.00%
05/04/2016After Market$-0.29-20.83%
02/10/2016After Market$-0.35-34.62%
11/03/2015After Market$-0.22-10.00%
07/29/2015After Market$-0.1353.57%
05/06/2015After Market$-0.244.00%
02/19/2015Before Market$-0.200.00%
10/27/2014Before Market$-0.0489.74%
08/07/2014---$-0.6412.33%
05/08/2014---$-0.49-68.97%
02/13/2014---$-0.23-15.00%
11/07/2013---$-0.1743.33%
07/31/2013---$-0.1150.00%
05/09/2013---$-0.1540.00%
02/12/2013---$-0.23-4.55%
11/07/2012---$-0.1913.64%
08/02/2012---$-0.28-3.70%
05/08/2012---$-0.28-75.00%
02/14/2012---$-0.20-5.26%
11/04/2011---$-0.11-57.14%
08/04/2011---$-0.050.00%
05/05/2011---$0.00---
02/10/2011---$0.08500.00%
11/03/2010---$0.11266.67%
08/05/2010---$0.04-55.56%
05/04/2010---$0.02-77.78%
02/16/2010---$-0.34-112.50%
11/02/2009---$-0.286.67%
08/10/2009---$-0.46-12.20%
04/29/2009---$-0.24-9.09%
02/11/2009---$-0.2822.22%
10/30/2008---$-0.41-2.50%
08/05/2008---$-0.5119.05%
05/01/2008---$-0.7213.25%
02/14/2008---$-0.781.27%
11/08/2007---$-0.8215.46%
08/02/2007---$-0.6025.93%
05/01/2007---$-0.61-8.93%
02/07/2007---$-0.5415.63%
11/02/2006---$-0.5542.11%
08/03/2006---$-1.11-33.73%
05/18/2006---$-385.61---

More About Vanda Pharmaceuticals Inc

Website
https://www.vandapharma.com
Country
USA
Full Time Employees
368

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

“Vanda Pharmaceuticals Inc Earnings” Can Refer to the Vanda Pharmaceuticals Inc Earnings Date

Some people say “Vanda Pharmaceuticals Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Vanda Pharmaceuticals Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Vanda Pharmaceuticals Inc Stock on the Earnings Date

If you own Vanda Pharmaceuticals Inc stock (VNDA) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Vanda Pharmaceuticals Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Vanda Pharmaceuticals Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Vanda Pharmaceuticals Inc Earnings

You can contact us any time if you would like to ask questions about Vanda Pharmaceuticals Inc earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.